Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03515837 · ClinicalTrials.gov registry record · Phase 3
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)
A Phase 3 study of Non-Small Cell Lung Cancer, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 3
- Development phase
- 492
- Enrollment target
- 20
- Study locations
NCT03515837 is a Phase 3 study of Non-Small Cell Lung Cancer that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 492 participants, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (25% lower). The trial reports 20 study locations across 12 states.
The verdict
NCT03515837, a Phase 3 study of Non-Small Cell Lung Cancer, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 492 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following types of tyrosine kinase inhibitor (TKI)-resistant, epidermal growth factor receptor (EGFR)-mutated, metastatic non-squamous non-small cell lung cancer (NSCLC) tumors: 1) TKI-failures (including osimertinib \[TAGRISSO®\] failure) with T790M-negative mutation tumors, 2) T790M-positive mutation tumors with prior exposure to osimertinib, and 3) first-line osimertinib failure regardless of T790M mutation status. The primary study hypotheses are that the combination of pembrolizumab plus chemotherapy has superior efficacy compared to saline placebo plus chemotherapy in terms of: 1) Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) based on blinded independent central review, and 2) Overall Survival (OS). This study will be considered to have met its success criteria if the combination of pembrolizumab plus chemotherapy is superior to saline placebo plus chemotherapy in terms of PFS or OS. Upon study completion, participants are discontinued and may be enrolled in a pembrolizumab extension study, if available.
Conditions Studied
Interventions
- BIOLOGICAL pembrolizumab
- DRUG cisplatin
- DRUG carboplatin
- DRUG pemetrexed
- DRUG saline solution
Study Locations (20)
California
- Cedars-Sinai Medical Center ( Site 0070) - Los Angeles
- Pacific Cancer Care ( Site 0058) - Monterey
- UC Irvine Medical Center/Chao Family Comprehensive Cancer Center ( Site 0092) - Orange
- St. Joseph Heritage Healthcare ( Site 0003) - Santa Rosa
New York
- New York Oncology Hematology P.C ( Site 8000) - Albany
- Monter Cancer Center ( Site 0054) - Lake Success
- Memorial Sloan Kettering Cancer Center-Rockerfeller Patient Pavilion ( Site 0049) - New York
- White Plains Hospital Center for Cancer Care ( Site 0014) - White Plains
Oregon
- Providence Portland Medical Center ( Site 0097) - Portland
- Kaiser Permanente Northwest ( Site 0037) - Portland
Texas
- Parkland Health & Hospital System ( Site 2102) - Dallas
- University of Texas Southwestern Medical Center at Dallas ( Site 0035) - Dallas
Illinois
- North Shore University Health System ( Site 0030) - Evanston
Iowa
- Siouxland Regioinal Cancer Center dba June E. Nylen Cancer Center ( Site 0065) - Sioux City
Minnesota
- Southdale Cancer Care, University of Minnesota Medical Center- Edina ( Site 0048) - Edina
Missouri
- Saint Lukes Hospital of Kansas City ( Site 0060) - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 492 participants |
| Start Date | 2018-06-29 |
| Est. Completion | 2023-10-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03515837
The ClinicalTrials.gov registry entry for NCT03515837 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 492 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 658-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (25% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which pembrolizumab is the first listed.
NCT03515837 reports 20 study locations spanning 12 distinct geographic areas - top geographies include California, New York, Oregon.
Frequently Asked Questions
What is clinical trial NCT03515837 about?
NCT03515837 is a clinical study titled "Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)". The purpose of this study is to evaluate the efficacy and safety of pemetrexed plus platinum chemotherapy (carboplatin or cisplatin) with or without pembrolizumab (MK-3475; KEYTRUDA®) in the treatment of adults with the following types of tyrosine kinase inhibitor (TKI)-resistant, epidermal growth f...
What is the current status of trial NCT03515837?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 492 participants. The study started on 2018-06-29. Estimated completion is 2023-10-02.
What conditions does trial NCT03515837 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT03515837?
The interventions under investigation include: pembrolizumab (BIOLOGICAL), cisplatin (DRUG), carboplatin (DRUG), pemetrexed (DRUG), saline solution (DRUG).
Who is sponsoring clinical trial NCT03515837?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03515837 being conducted?
This trial has 20 study locations across California, Illinois, Iowa, Minnesota, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
RECRUITING · Phase 3
-
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
RECRUITING · Phase 3
-
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
RECRUITING · Phase 3
-
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
RECRUITING · Phase 3
-
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.